Tumor Treating Fields (TTFields), a low intensity electric field therapy delivered through scalp arrays, started alongside chemoradiation matched the FDA approved maintenance schedule (p=0.519), and shares fell roughly 25% in premarket trading on the June 18, 2026 readout.
Novocure's wearable Optune Gio device delivers Tumor Treating Fields (TTFields), low-intensity alternating electric fields applied through transducer arrays on the scalp. The phase 3 Trident trial asked a specific question of that device: would starting it earlier, concurrent with the chemoradiation phase of newly diagnosed glioblastoma treatment, beat the current standard of starting it later, in the maintenance phase. The answer, delivered on June 18, 2026, was no. Median overall survival came in at 17.7 months in the early-start arm versus 17.5 months in the maintenance arm, a gap of roughly six days and a p-value of 0.519, according to Fierce Biotech's report on the company disclosure.
The 0.2-month delta is the load-bearing fact. It is not a positive result for the early-start hypothesis, and it is not a negative result for the device. Both arms of Trident received TTFields, just at different points in the treatment sequence. The maintenance arm, the schedule that the FDA has approved for newly diagnosed supratentorial glioblastoma after maximal debulking and concurrent chemoradiation, is essentially unchanged by this readout. The thing that failed is the case for moving the start of TTFields earlier.
The patient context sharpens the result rather than softens it. Glioblastoma carries a five-year survival in the 5 to 7 percent range, and median overall survival on the current temozolomide plus maintenance TTFields standard sits in the high-teens months. A six-day gap is the kind of result that can be spun either way, and the field will likely do both. Novocure's framing will probably emphasize that both arms performed in a clinically meaningful range, which is true. Critics will point out that 17.5 months in the maintenance arm sits at the low end of historical controls and that the early-start arm did not separate from it, which is also true. Both readings are defensible, and both belong in the conversation.
The forward-looking question is where Trident's data may still produce usable signal: patient subgroups. Novocure has indicated it plans to publish subgroup analyses from the trial, and that is the analysis worth tracking next. If a specific subgroup, defined by MGMT methylation status, extent of resection, tumor location, or age band, shows a real early-start benefit, the device label could be expanded to support earlier use in that group. If the subgroups come back flat, the early-start hypothesis is genuinely closed, and the TTFields franchise reverts to the maintenance standard it already has.
The market is pricing much of that disappointment already. Novocure shares fell roughly 25 percent in premarket trading on the news, according to Fierce Biotech's report on the company disclosure, a reaction that treats the result as a meaningful negative for the device franchise. That reaction conflates a timing-arm miss with a broader TTFields failure, and is the framing risk in the wire coverage. For clinicians, the practical read is unchanged: keep starting TTFields in the maintenance phase per the current label. For investors, the read is that Novocure's next move is a subgroup cut, not a label change. For patients with newly diagnosed glioblastoma, the read is that TTFields is still on the table, and the timing of when it starts is not, on this evidence, something to push earlier outside a clinical trial.